Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 10 |
NetGPI | no | yes: 0, no: 10 |
Term | Name | Level | Count |
---|---|---|---|
GO:0016020 | membrane | 2 | 11 |
GO:0110165 | cellular anatomical entity | 1 | 11 |
Related structures:
AlphaFold database: A4HID6
Term | Name | Level | Count |
---|---|---|---|
GO:0003824 | catalytic activity | 1 | 11 |
GO:0016491 | oxidoreductase activity | 2 | 11 |
GO:0140575 | transmembrane monodehydroascorbate reductase activity | 3 | 11 |
GO:0005488 | binding | 1 | 1 |
GO:0020037 | heme binding | 4 | 1 |
GO:0046906 | tetrapyrrole binding | 3 | 1 |
GO:0097159 | organic cyclic compound binding | 2 | 1 |
GO:1901363 | heterocyclic compound binding | 2 | 1 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_NRD_NRD_1 | 180 | 182 | PF00675 | 0.259 |
CLV_NRD_NRD_1 | 28 | 30 | PF00675 | 0.252 |
CLV_NRD_NRD_1 | 77 | 79 | PF00675 | 0.409 |
CLV_NRD_NRD_1 | 87 | 89 | PF00675 | 0.523 |
CLV_PCSK_KEX2_1 | 175 | 177 | PF00082 | 0.346 |
CLV_PCSK_KEX2_1 | 180 | 182 | PF00082 | 0.187 |
CLV_PCSK_KEX2_1 | 28 | 30 | PF00082 | 0.251 |
CLV_PCSK_KEX2_1 | 77 | 79 | PF00082 | 0.422 |
CLV_PCSK_PC1ET2_1 | 175 | 177 | PF00082 | 0.346 |
CLV_PCSK_PC7_1 | 176 | 182 | PF00082 | 0.187 |
CLV_PCSK_SKI1_1 | 166 | 170 | PF00082 | 0.382 |
DOC_ANK_TNKS_1 | 28 | 35 | PF00023 | 0.433 |
DOC_MAPK_gen_1 | 28 | 35 | PF00069 | 0.531 |
DOC_USP7_MATH_1 | 87 | 91 | PF00917 | 0.598 |
DOC_WW_Pin1_4 | 14 | 19 | PF00397 | 0.675 |
DOC_WW_Pin1_4 | 167 | 172 | PF00397 | 0.387 |
DOC_WW_Pin1_4 | 83 | 88 | PF00397 | 0.626 |
LIG_Actin_WH2_2 | 152 | 168 | PF00022 | 0.461 |
LIG_Actin_WH2_2 | 66 | 82 | PF00022 | 0.414 |
LIG_EH1_1 | 56 | 64 | PF00400 | 0.279 |
LIG_FHA_1 | 187 | 193 | PF00498 | 0.374 |
LIG_FHA_1 | 217 | 223 | PF00498 | 0.455 |
LIG_FHA_2 | 2 | 8 | PF00498 | 0.715 |
LIG_Integrin_RGD_1 | 20 | 22 | PF01839 | 0.296 |
LIG_LIR_Gen_1 | 129 | 137 | PF02991 | 0.270 |
LIG_LIR_Gen_1 | 47 | 58 | PF02991 | 0.283 |
LIG_LIR_Nem_3 | 129 | 133 | PF02991 | 0.324 |
LIG_LIR_Nem_3 | 134 | 140 | PF02991 | 0.347 |
LIG_LIR_Nem_3 | 47 | 53 | PF02991 | 0.298 |
LIG_PDZ_Class_2 | 230 | 235 | PF00595 | 0.201 |
LIG_SH2_CRK | 56 | 60 | PF00017 | 0.239 |
LIG_SH2_NCK_1 | 50 | 54 | PF00017 | 0.287 |
LIG_SH2_PTP2 | 130 | 133 | PF00017 | 0.187 |
LIG_SH2_STAP1 | 207 | 211 | PF00017 | 0.371 |
LIG_SH2_STAP1 | 50 | 54 | PF00017 | 0.287 |
LIG_SH2_STAT5 | 130 | 133 | PF00017 | 0.288 |
LIG_SH2_STAT5 | 167 | 170 | PF00017 | 0.546 |
LIG_SH2_STAT5 | 185 | 188 | PF00017 | 0.298 |
LIG_SH2_STAT5 | 50 | 53 | PF00017 | 0.413 |
LIG_SH3_2 | 171 | 176 | PF14604 | 0.488 |
LIG_SH3_3 | 165 | 171 | PF00018 | 0.483 |
LIG_SUMO_SIM_anti_2 | 189 | 194 | PF11976 | 0.201 |
LIG_SUMO_SIM_anti_2 | 219 | 225 | PF11976 | 0.349 |
LIG_SUMO_SIM_par_1 | 219 | 225 | PF11976 | 0.201 |
LIG_TRFH_1 | 167 | 171 | PF08558 | 0.407 |
LIG_TYR_ITIM | 128 | 133 | PF00017 | 0.344 |
LIG_WRC_WIRS_1 | 112 | 117 | PF05994 | 0.344 |
LIG_WRC_WIRS_1 | 23 | 28 | PF05994 | 0.537 |
MOD_CDC14_SPxK_1 | 17 | 20 | PF00782 | 0.424 |
MOD_CDC14_SPxK_1 | 86 | 89 | PF00782 | 0.515 |
MOD_CDK_SPK_2 | 83 | 88 | PF00069 | 0.420 |
MOD_CDK_SPxK_1 | 14 | 20 | PF00069 | 0.442 |
MOD_CDK_SPxK_1 | 83 | 89 | PF00069 | 0.491 |
MOD_CK1_1 | 225 | 231 | PF00069 | 0.292 |
MOD_CK2_1 | 1 | 7 | PF00069 | 0.685 |
MOD_CK2_1 | 99 | 105 | PF00069 | 0.359 |
MOD_GlcNHglycan | 186 | 189 | PF01048 | 0.292 |
MOD_GlcNHglycan | 224 | 227 | PF01048 | 0.201 |
MOD_GlcNHglycan | 46 | 49 | PF01048 | 0.413 |
MOD_GSK3_1 | 139 | 146 | PF00069 | 0.391 |
MOD_GSK3_1 | 212 | 219 | PF00069 | 0.344 |
MOD_GSK3_1 | 222 | 229 | PF00069 | 0.246 |
MOD_GSK3_1 | 44 | 51 | PF00069 | 0.440 |
MOD_GSK3_1 | 83 | 90 | PF00069 | 0.427 |
MOD_NEK2_1 | 1 | 6 | PF00069 | 0.629 |
MOD_NEK2_1 | 143 | 148 | PF00069 | 0.221 |
MOD_NEK2_1 | 216 | 221 | PF00069 | 0.371 |
MOD_NEK2_1 | 44 | 49 | PF00069 | 0.443 |
MOD_PKA_2 | 87 | 93 | PF00069 | 0.468 |
MOD_Plk_4 | 111 | 117 | PF00069 | 0.399 |
MOD_Plk_4 | 151 | 157 | PF00069 | 0.325 |
MOD_Plk_4 | 212 | 218 | PF00069 | 0.355 |
MOD_ProDKin_1 | 14 | 20 | PF00069 | 0.601 |
MOD_ProDKin_1 | 167 | 173 | PF00069 | 0.202 |
MOD_ProDKin_1 | 83 | 89 | PF00069 | 0.543 |
MOD_SUMO_rev_2 | 17 | 26 | PF00179 | 0.343 |
MOD_SUMO_rev_2 | 170 | 177 | PF00179 | 0.209 |
TRG_ENDOCYTIC_2 | 130 | 133 | PF00928 | 0.470 |
TRG_ENDOCYTIC_2 | 137 | 140 | PF00928 | 0.344 |
TRG_ENDOCYTIC_2 | 50 | 53 | PF00928 | 0.384 |
TRG_ENDOCYTIC_2 | 56 | 59 | PF00928 | 0.306 |
TRG_ER_diArg_1 | 179 | 181 | PF00400 | 0.201 |
TRG_ER_diArg_1 | 28 | 30 | PF00400 | 0.293 |
TRG_ER_diArg_1 | 76 | 78 | PF00400 | 0.466 |
TRG_Pf-PMV_PEXEL_1 | 95 | 99 | PF00026 | 0.447 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0S4JNM4 | Bodo saltans | 27% | 99% |
A0A1X0P2F3 | Trypanosomatidae | 24% | 95% |
A0A3Q8IC17 | Leishmania donovani | 64% | 100% |
A0A3R7RSY6 | Trypanosoma rangeli | 28% | 98% |
A4I5N2 | Leishmania infantum | 66% | 100% |
C9ZR03 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 21% | 98% |
E9B0X7 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 67% | 100% |
Q4Q789 | Leishmania major | 68% | 96% |
V5BPF8 | Trypanosoma cruzi | 27% | 98% |